HIA
PTCT icon

HFM Investment Advisors’s PTC Therapeutics PTCT Stock Holding History

HFM Investment Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$735 Buy
9
+5
+125% +$361 ﹤0.01% 849
2026
Q1 		$273 Hold
4
– – ﹤0.01% 902
2025
Q4 		$304 Sell
4
-1
-20% -$73 ﹤0.01% 892
2025
Q3 		$307 Hold
5
– – ﹤0.01% 857
2025
Q2 		$244 Buy
5
+3
+150% +$142 ﹤0.01% 923
2025
Q1 		$102 Buy
+2
New +$100 ﹤0.01% 852

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

HFM Investment Advisors's PTCT Position: Q2 2026 in Review

HFM Investment Advisors increased its PTC Therapeutics (PTCT) stake by 125% in Q2 2026, buying an estimated $361 and bringing the position to 9 shares worth $735. The position accounts for ﹤0.01% of the portfolio, ranked #849.

HFM Investment Advisors first reported a position in PTCT in Q1 2025 and has held it in 6 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • HFM Investment Advisors held 9 shares of PTC Therapeutics worth $735 as of Q2 2026.
  • HFM Investment Advisors bought 5 PTC Therapeutics shares in Q2 2026, an estimated $361.
  • PTC Therapeutics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #849 holding.
  • HFM Investment Advisors first reported a position in PTC Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.